Page last updated: 2024-08-25

methotrexate and Non-alcoholic Fatty Liver Disease

methotrexate has been researched along with Non-alcoholic Fatty Liver Disease in 17 studies

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's10 (58.82)24.3611
2020's7 (41.18)2.80

Authors

AuthorsStudies
Cheema, HI; Dranoff, JA; Haselow, D1
Arias-de la Rosa, I; Barbarroja, N; Collantes-Estévez, E; Cuesta-López, L; López-Pedrera, C; Pérez-Sánchez, C; Ruiz-Ponce, M1
Aubin, F; Avouac, J; Di Martino, V; Lioté, F; Thévenot, T; Verhoeven, DW; Verhoeven, F; Vuitton, L; Wendling, D1
Ishiwata, S; Kuroda, M; Migita, K; Miyata, M; Ohira, H; Tasaki, K1
Aspinall, RJ; Hamilton, J; Livesey, A; Raahimi, MM; Shipman, AR1
Arias-de la Rosa, I; Barbarroja, N; Barranco, A; Collantes-Estévez, E; Cuesta-López, L; Escudero-Contreras, A; Gahete, MD; Herman-Sánchez, N; López-Medina, C; López-Montilla, MD; López-Pedrera, C; Lucendo, AJ; Navarro, P; Ortiz-Buitrago, P; Pérez-Sánchez, C; Ruiz-Ponce, M1
Hu, Z; Jenkins, B; Koulman, A; Lenaerts, AS; Liang, TJ; Morell, CM; Park, SB; Tilson, SG; Vallier, L1
Alazawi, W; Cho, W; Shetty, A; Syn, WK1
Arima, N; Fujiyama, S; Ito, M; Kamo, Y; Mori, S; Ueki, Y1
Bigi, L; Conti, A; Lasagni, C; Pellacani, G1
Pais, R; Ratziu, V; Rusu, E1
Chan, GY; Koh, ET; Leong, KP; Sakthiswary, R; Thong, BY1
Anumol, T; Canet, MJ; Cherrington, NJ; Clarke, JD; Goedken, MJ; Hardwick, RN; Lake, AD; Merrell, MD; Snyder, SA; Street, SM1
Cherrington, NJ; Coen, M; Goedken, MJ; Hardwick, RN; Holmes, E; Jin, Z; Kyriakides, M1
Aithal, GP; Dawwas, MF1
Ferrazzi, A; Girolomoni, G; Gisondi, P1
Larrain, S; Rinella, ME1

Reviews

8 review(s) available for methotrexate and Non-alcoholic Fatty Liver Disease

ArticleYear
Review of existing evidence demonstrates that methotrexate does not cause liver fibrosis.
    Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2022, Volume: 70, Issue:7

    Topics: Biopsy; Humans; Liver; Liver Cirrhosis; Methotrexate; Non-alcoholic Fatty Liver Disease

2022
Nonalcoholic fatty liver disease in inflammatory arthritis: Relationship with cardiovascular risk.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Biological Products; Cardiovascular Diseases; Heart Disease Risk Factors; Humans; Inflammation; Leflunomide; Liver Cirrhosis; Methotrexate; Non-alcoholic Fatty Liver Disease; Risk Factors

2022
Busting the myth of methotrexate chronic hepatotoxicity.
    Nature reviews. Rheumatology, 2023, Volume: 19, Issue:2

    Topics: Biopsy; Chemical and Drug Induced Liver Injury; Humans; Liver Cirrhosis; Methotrexate; Non-alcoholic Fatty Liver Disease

2023
Liver fibrosis for the dermatologist: a review.
    Clinical and experimental dermatology, 2023, Mar-22, Volume: 48, Issue:4

    Topics: Dermatologists; Fibrosis; Humans; Liver Cirrhosis; Methotrexate; Non-alcoholic Fatty Liver Disease; Psoriasis

2023
Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease.
    The American journal of the medical sciences, 2017, Volume: 354, Issue:2

    Topics: Antirheumatic Agents; Chemical and Drug Induced Liver Injury; Dermatologic Agents; Diabetes Mellitus; Humans; Metabolic Syndrome; Methotrexate; Non-alcoholic Fatty Liver Disease; Obesity; Risk Factors

2017
The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease.
    Clinics in liver disease, 2014, Volume: 18, Issue:1

    Topics: Acetaminophen; Anesthetics; Animals; Chemical and Drug Induced Liver Injury; Fatty Liver; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Insulin Resistance; Male; Metabolic Syndrome; Methotrexate; Non-alcoholic Fatty Liver Disease; Obesity; Prevalence; Risk Factors; Trans-Activators; Viral Regulatory and Accessory Proteins

2014
Metabolic comorbidities and psoriasis.
    Acta dermatovenerologica Croatica : ADC, 2010, Volume: 18, Issue:4

    Topics: Arthritis, Psoriatic; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Fatty Liver; Humans; Hypertriglyceridemia; Immunosuppressive Agents; Insulin Resistance; Metabolic Syndrome; Methotrexate; Non-alcoholic Fatty Liver Disease; Obesity; Psoriasis; Risk Factors

2010
A myriad of pathways to NASH.
    Clinics in liver disease, 2012, Volume: 16, Issue:3

    Topics: Amiodarone; Anti-Retroviral Agents; Bacterial Infections; Cannabis; Diet; Fatty Liver; Genetic Diseases, Inborn; Glucocorticoids; Humans; Hypothyroidism; Insulin Resistance; Intestinal Diseases; Lipid Metabolism; Metabolic Syndrome; Methotrexate; Non-alcoholic Fatty Liver Disease; Occupational Diseases; Perhexiline

2012

Other Studies

9 other study(ies) available for methotrexate and Non-alcoholic Fatty Liver Disease

ArticleYear
Hepatic failure in a patient with rheumatoid arthritis treated with methotrexate: A case report.
    Medicine, 2023, Jan-27, Volume: 102, Issue:4

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Female; Humans; Liver Failure; Methotrexate; Non-alcoholic Fatty Liver Disease

2023
Decoding clinical and molecular pathways of liver dysfunction in Psoriatic Arthritis: Impact of cumulative methotrexate doses.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 168

    Topics: Arthritis, Psoriatic; Cross-Sectional Studies; Humans; Longitudinal Studies; Methotrexate; Non-alcoholic Fatty Liver Disease; Psoriasis; Retrospective Studies

2023
Modeling PNPLA3-Associated NAFLD Using Human-Induced Pluripotent Stem Cells.
    Hepatology (Baltimore, Md.), 2021, Volume: 74, Issue:6

    Topics: Cell Differentiation; Cell Line; CRISPR-Cas Systems; Ethanol; Gene Knockout Techniques; Genetic Predisposition to Disease; Hepatocytes; Humans; Induced Pluripotent Stem Cells; Lipase; Lipid Metabolism; Loss of Function Mutation; Membrane Proteins; Methotrexate; Non-alcoholic Fatty Liver Disease; Polymorphism, Single Nucleotide; Toxicity Tests, Acute

2021
Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment.
    PloS one, 2018, Volume: 13, Issue:8

    Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; Chemical and Drug Induced Liver Injury; Female; Humans; Liver; Male; Methotrexate; Middle Aged; Non-alcoholic Fatty Liver Disease; Risk Factors; Transaminases

2018
Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies.
    The Journal of dermatological treatment, 2018, Volume: 29, Issue:sup2

    Topics: Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Therapy; Comorbidity; Cyclosporine; Etanercept; Female; Hepatitis B; Hepatitis C; Humans; Infliximab; Interleukin-17; Latent Tuberculosis; Male; Methotrexate; Middle Aged; Non-alcoholic Fatty Liver Disease; Psoriasis; Ustekinumab

2018
Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis.
    TheScientificWorldJournal, 2014, Volume: 2014

    Topics: Adult; Aged; Alanine Transaminase; Arthritis, Rheumatoid; Case-Control Studies; Cohort Studies; Female; Humans; Male; Methotrexate; Middle Aged; Non-alcoholic Fatty Liver Disease; Risk Factors; Singapore

2014
Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis.
    Toxicological sciences : an official journal of the Society of Toxicology, 2014, Volume: 142, Issue:1

    Topics: Animals; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Feces; Kidney; Liver; Male; Methotrexate; Multidrug Resistance-Associated Protein 2; Non-alcoholic Fatty Liver Disease; Rats, Sprague-Dawley; Tissue Distribution

2014
Systems level metabolic phenotype of methotrexate administration in the context of non-alcoholic steatohepatitis in the rat.
    Toxicological sciences : an official journal of the Society of Toxicology, 2014, Volume: 142, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Energy Metabolism; Folic Acid; Liver; Magnetic Resonance Spectroscopy; Male; Metabolomics; Methotrexate; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Rats, Sprague-Dawley; Tissue Distribution

2014
End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome.
    Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:8

    Topics: Aged; Body Mass Index; Cholangitis, Sclerosing; Diabetes Mellitus; End Stage Liver Disease; Female; Humans; Immunosuppressive Agents; Liver Diseases, Alcoholic; Liver Transplantation; Logistic Models; Male; Metabolic Syndrome; Methotrexate; Middle Aged; Non-alcoholic Fatty Liver Disease; Odds Ratio; Risk Factors; United States

2014